Triplet therapy with darolutamide (DARO), androgen-deprivation therapy (ADT) and docetaxel (DOC) is a game changer in the treatment of metastatic hormone-sensitive prostate cancer
Dive into the groundbreaking results presented by Professor Fred Saad at ESMO 2023, which highlight the subsequent analysis of the ARASENS trial. This trial is pioneering in its approach, being the first to compare a triplet versus a duplet method for treating metastatic hormone-sensitive prostate cancer. The latest data reveals an impressive improvement in overall survival, exceeding 30% for the entire population, irrespective of the patients’ risk and volume levels.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.